MacroGenics to Participate in Two Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
MacroGenics (MGNX) PT Lowered to $42 at Stifel; Reiterates Buy
March 1, 2017 9:03 AM ESTStifel lowered its price target on MacroGenics (NASDAQ: MGNX) to $42.00 (from $51.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "Managements relatively quiet 4Q16 earnings announcement/call was expected following the comprehensive pipeline update provided at the December 2016 R&D Day. The... More
